Payment overview · 2025
General Payments
$747.94
35 reported records · 8 companies
Healthcare provider profile · identity verified
Brian E Winn, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1629067251
Verified facts
What the public records show
CMS Open Payments records show Brian E Winn, M.D. received $747.94 in general payments during 2025 across 35 reported records.
Lilly USA, LLC accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $196.53 | 26.3% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $169.46 | 22.7% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.48 | 20.1% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $97.02 | 13.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.88 | 7.7% | 2 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $32.37 | 4.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $26.00 | 3.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.20 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $747.94 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $177.07 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $171.97 | 10 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $99.10 | 5 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $97.02 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.19 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $96.19 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.27 | 3 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $51.38 | 3 | 2025 |
Source payment records
|
|||||
| Tyenne Normalized: tyenne |
Biological | Fresenius Kabi USA, LLC | $32.37 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 389 | 58 |
| Alprazolam | Alprazolam | 369 | 63 |
| Prednisone | Prednisone | 328 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 68 |
| Gabapentin | Gabapentin | 246 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 207 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 194 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 25 |
| Tramadol Hcl | Tramadol Hcl | 157 | 31 |
| Omeprazole | Omeprazole | 148 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 29 |
| Lisinopril | Lisinopril | 145 | 39 |
| Furosemide | Furosemide | 125 | 36 |
| Trazodone Hcl | Trazodone Hcl | 120 | 25 |
| Methotrexate | Methotrexate Sodium | 119 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 32 |
| Metformin Hcl | Metformin Hcl | 102 | 28 |
| Carvedilol | Carvedilol | 99 | 28 |
| Simvastatin | Simvastatin | 95 | 30 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 94 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 23 |
| Montelukast Sodium | Montelukast Sodium | 86 | 24 |
| Sertraline Hcl | Sertraline Hcl | 86 | 21 |
| Glimepiride | Glimepiride | 85 | 22 |
| Losartan Potassium | Losartan Potassium | 84 | 23 |
| Famotidine | Famotidine | 83 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 25 |
| Pregabalin | Pregabalin | 80 | 19 |
| Clonazepam | Clonazepam | 76 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 70 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 11 |
| Celecoxib | Celecoxib | 67 | 18 |
| Allopurinol | Allopurinol | 65 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 13 |
| Ondansetron Odt | Ondansetron | 65 | 26 |
| Azithromycin | Azithromycin | 61 | 47 |
| Lorazepam | Lorazepam | 56 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 13 |
| Potassium Chloride | Potassium Chloride | 51 | 18 |
| Methylphenidate Hcl | Methylphenidate Hcl | 48 | suppressed |
| Topiramate | Topiramate | 48 | 11 |
| Eliquis | Apixaban | 46 | suppressed |
| Meloxicam | Meloxicam | 46 | 14 |
| Metformin Hcl Er | Metformin Hcl | 46 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 17 |
| Spironolactone | Spironolactone | 42 | 11 |
| Levofloxacin | Levofloxacin | 41 | 32 |
| Atenolol | Atenolol | 39 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 13 |
| Alendronate Sodium | Alendronate Sodium | 38 | 11 |
| Ozempic | Semaglutide | 37 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Azathioprine | Azathioprine | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 23 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 14 |
| Naproxen | Naproxen | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 11 |
| Baclofen | Baclofen | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Benlysta | Belimumab | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Enbrel Sureclick | Etanercept | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Rinvoq | Upadacitinib | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Humira Pen | Adalimumab | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | 11 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Actemra Actpen | Tocilizumab | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humira(Cf) Pen | Adalimumab | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $747.94 · 35 records | Lilly USA, LLC | CAPVAXIVE, COSENTYX, GARDASIL 9, KRYSTEXXA, MOUNJARO, Ozempic, RINVOQ, Rybelsus, SKYRIZI, Tyenne, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error